HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pharmaceutical Outsourcing

1,900.208

+15.4270.82%

Number of Gainers:4

Number of Losers:4

Number of Flat:- -

PE:- -

High:1,909.077

Open:1,884.255

Low:1,862.510

Close:1,884.782

Loading ...

Wuxi Biologics (Cayman) Inc. Conducted Annual General Meeting

WuXi Biologics - Sherry Xuejun Gu Was Appointed as an Executive Director

THOMSON REUTERS

Legend Biotech Corporation Names Peter Salovey as Lead Independent Director

WuXi Biologics Grants 64,117 Restricted Shares Under Incentive Scheme

MT Newswires Live

BRIEF-JPMorgan Chase & Co's Long Position In Wuxi Apptec H-Shares Increases To 7.12% On May 30 - HKEX

WuXi Biologics Announces New Compensation Plan with 64,117 Restricted Shares Granted Under Award Scheme

Genscript Biotech's Myeloma Drug Shows Progression-Free Survival in One-Third of Patients During Study

MT Newswires Live

VIVA Biotech Holdings Issues Clarification on Connected Transaction with Nanjing Entities

Legend Biotech Announces Promising Phase 1 Results for LB2102 CAR-T Therapy in Lung Cancer Patients

Frontage Holdings Corporation Expands with New State-of-the-Art CRDMO Facility in Exton, PA

Wuxi Biologics Files Next Day Disclosure to HKEX: Announces Issuance of 3,653,100 New Shares at HKD 1.29-1.98

Frontage Holdings Corporation Conducted Annual General Meeting

BRIEF-Viva Biotech Says Hangzhou Viva Zongchen Agreed To Invest RMB25.0 Million To Fund

VIVA Biotech - Fund Refers to Limited Partnership Fund to Be Named Nanjing Honghui Weitai Venture Capital Fund Partnership

THOMSON REUTERS

VIVA Biotech - Hangzhou Viva Zongchen Agreed to Invest RMB25.0 Mln to Fund

THOMSON REUTERS

WuXi AppTec Cuts Conversion Price of Zero-Coupon Bonds Due This Year

MT Newswires Live

Joinn Laboratories Affiliate Buys Deposit Products for 440 Million Yuan; Hong Kong Shares Up 7%

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1576/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1576","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","market":"HK","secType":"PLATE","nameCN":"Pharmaceutical Outsourcing","latestPrice":1900.208,"timestamp":1749197315245,"preClose":1884.7815,"halted":0,"volume":105045001,"delay":0,"changeRate":0.008185,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":15.426514,"latestTime":"06-06 16:00:00","open":1884.255,"high":1909.0767,"low":1862.5104,"amount":2141380216,"amplitude":0.024706,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1749432600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1749173400000,1749182400000],[1749186000000,1749196800000]],"pbRate":2.188616,"peRate":10.448464,"turnoverRate":0.008537,"increases":4,"decrements":4,"flats":0,"marketCap":411253196800,"floatMarketCap":176638741888},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","high":1909.0767,"amplitude":0.024706,"preClose":1884.7815,"low":1862.5104,"pbRate":"2.188616","latestPrice":1900.208,"volume":105045001,"delay":0,"open":1884.255,"prevYearClose":1395.7731,"prevWeekClose":1859.052,"prevMonthClose":1859.052,"prevQuarterClose":1941.338,"fiveDayClose":1859.052,"twentyDayClose":1673.767,"sixtyDayClose":1793.042,"secType":"PLATE","market":"HK","turnoverRate":0.008537,"peRate":10.448464,"marketCap":411253196800,"floatMarketCap":176638741888,"timestamp":1749197315245,"nameCN":"Pharmaceutical Outsourcing"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1576\",,,,undefined,":{"bkCode":"BK1576","up":4,"down":4,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1576\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2541852348","title":"Wuxi Biologics (Cayman) Inc. Conducted Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2541852348","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541852348?lang=en_us&edition=fundamental","pubTime":"2025-06-06 19:47","pubTimestamp":1749210441,"startTime":"0","endTime":"0","summary":"WuXi Biologics  Inc. held its annual general meeting on June 6, 2025. All proposed resolutions were approved, including the retirement of Dr. Weichang Zhou as a non-executive Director and a member of the Strategy Committee. Dr. Sherry Xuejun Gu was appointed as an executive Director and a member of the Strategy Committee, while Dr. Jue Chen was appointed as a member of the Nomination Committee.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics  Inc. published the original content used to generate this news brief on June 06, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nNDLYmd3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1576","LU0181495838.USD","LU0456827905.SGD","LU0708995583.HKD","LU2039709279.SGD","LU0516422440.USD","LU0856984785.SGD","BK1610","LU0516423174.USD","LU1880383366.USD","LU0979878070.USD","LU1794554557.SGD","LU0320764599.SGD","SG9999002562.SGD","LU0348825331.USD","BK1589","LU0327786744.USD","LU1688375341.USD","LU0051755006.USD","LU0417516738.SGD","LU1242518931.SGD","LU0307460666.USD","LU0043850808.USD","LU0516423091.SGD","LU0572944931.SGD","SG9999002463.SGD","LU0140636845.USD","LU0359201612.USD","LU0326950275.SGD","LU1242518857.USD","LU0823426480.USD","LU0819121731.USD","LU0359202008.SGD","02269","LU0456846285.SGD","LU0516422366.SGD","LU0052750758.USD","LU0417516902.SGD","LU0039217434.USD","LU0516422952.EUR","LU0348735423.USD","LU0588546209.SGD","LU1720050803.USD","LU0823426308.USD","IE00B0JY6N72.USD","BK1141","BK1521"],"gpt_icon":0},{"id":"2541285407","title":"WuXi Biologics -  Sherry Xuejun Gu Was Appointed as an Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2541285407","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541285407?lang=en_us&edition=fundamental","pubTime":"2025-06-06 19:45","pubTimestamp":1749210342,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nFWN3S90EH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0348825331.USD","LU0140636845.USD","BK1576","LU0039217434.USD","LU0307460666.USD","LU0823426308.USD","BK1610","LU0708995583.HKD","LU0856984785.SGD","LU0181495838.USD","LU0979878070.USD","LU0327786744.USD","BK1589","SG9999002562.SGD","LU0043850808.USD","LU0588546209.SGD","LU0572944931.SGD","LU0516423091.SGD","IE00B0JY6N72.USD","LU0348735423.USD","LU0417516902.SGD","LU1688375341.USD","LU0417516738.SGD","LU0456827905.SGD","SG9999002463.SGD","LU1242518857.USD","BK1141","BK1521","LU0819121731.USD","LU0516422366.SGD","LU0052750758.USD","LU0516422952.EUR","LU2039709279.SGD","LU1720050803.USD","LU0359201612.USD","LU0320764599.SGD","LU0823426480.USD","LU1880383366.USD","LU0456846285.SGD","LU1794554557.SGD","LU0051755006.USD","LU0359202008.SGD","LU0516423174.USD","LU1242518931.SGD","LU0516422440.USD","02269","LU0326950275.SGD"],"gpt_icon":0},{"id":"2541020258","title":"Legend Biotech Corporation Names Peter Salovey as Lead Independent Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2541020258","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541020258?lang=en_us&edition=fundamental","pubTime":"2025-06-05 20:22","pubTimestamp":1749126168,"startTime":"0","endTime":"0","summary":"Legend Biotech Corporation has announced the appointment of Peter Salovey, Ph.D., as Lead Independent Director, effective June 5, 2025. Dr. Salovey, President Emeritus of Yale University, has been serving as an independent director on the company's Board since August 2024. In his new role, he will act as a key liaison among the Board, management, and shareholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 05, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDLbMQPcZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1576","HK0000306701.USD","BK4585","BK4139","HK0000320264.USD","LEGN","01548","BK4505","HK0000306685.HKD","BK1141","BK4588","BK1583","HK0000320223.HKD"],"gpt_icon":0},{"id":"2541027167","title":"WuXi Biologics Grants 64,117 Restricted Shares Under Incentive Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2541027167","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541027167?lang=en_us&edition=fundamental","pubTime":"2025-06-05 19:50","pubTimestamp":1749124225,"startTime":"0","endTime":"0","summary":"WuXi Biologics (Cayman) (HKG:2269) approved the grant of 64,117 restricted shares to an employee under a restricted share award scheme, a Thursday Hong Kong bourse filing said.The grantee is not a director, chief executive or substantial shareholder of the vaccine maker.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1141","SG9999002562.SGD","BK1589","LU1242518857.USD","LU0181495838.USD","LU0359201612.USD","LU2039709279.SGD","02269","LU0140636845.USD","LU0856984785.SGD","LU0516422366.SGD","LU0516423174.USD","LU0043850808.USD","BK1610","IE00B0JY6N72.USD","LU0708995583.HKD","LU0307460666.USD","LU0572944931.SGD","LU0823426308.USD","LU0039217434.USD","LU0456827905.SGD","LU1242518931.SGD","LU0348825331.USD","LU0819121731.USD","LU0979878070.USD","LU1880383366.USD","LU0516422440.USD","LU0823426480.USD","LU0327786744.USD","LU1688375341.USD","LU0052750758.USD","BK1576","LU0417516738.SGD","LU0516422952.EUR","LU0417516902.SGD","LU1794554557.SGD","SG9999002463.SGD","LU0051755006.USD","LU0359202008.SGD","BK1521","LU0456846285.SGD","LU0588546209.SGD","LU0320764599.SGD","LU0348735423.USD","LU1720050803.USD","LU0516423091.SGD","LU0326950275.SGD"],"gpt_icon":0},{"id":"2541021021","title":"BRIEF-JPMorgan Chase & Co's Long Position In Wuxi Apptec H-Shares Increases To 7.12% On May 30 - HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2541021021","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541021021?lang=en_us&edition=fundamental","pubTime":"2025-06-05 18:34","pubTimestamp":1749119657,"startTime":"0","endTime":"0","summary":"BRIEF-JPMorgan Chase & Co's Long Position In Wuxi Apptec H-Shares Increases To 7.12% On May 30 - HKEXJune 5  - JPMORGAN CHASE & CO'S LONG POSITION IN H-SHARES OF WUXI APPTEC INCREASES TO 7.12% ON MAY 30 FROM 6.59% - HKEXFurther company coverage: 2359.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"94feda8dff1acbfa36f1d28f276c473d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nFWN3S70WK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1997244956.HKD","LU0052750758.USD","LU1997245094.SGD","LU0320764599.SGD","LU2242644610.SGD","LU1969619763.USD","LU2495084118.USD","BK1141","LU2488822045.USD","02359","LU2045819591.USD","LU1046422090.SGD","BK1583","LU0456842615.SGD","LU2125910500.SGD","LU0708995583.HKD","603259","BK0216","LU1997245177.USD","LU2328871848.SGD","BK1576"],"gpt_icon":0},{"id":"2541025421","title":"WuXi Biologics Announces New Compensation Plan with 64,117 Restricted Shares Granted Under Award Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2541025421","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541025421?lang=en_us&edition=fundamental","pubTime":"2025-06-05 17:40","pubTimestamp":1749116401,"startTime":"0","endTime":"0","summary":"WuXi Biologics  Inc., a company incorporated in the Cayman Islands, has announced the approval of a new grant of 64,117 restricted shares under its Restricted Share Award Scheme. The grant, approved by the Board on June 5, 2025, is subject to acceptance by the grantee. This decision aligns with the company's effort to allocate shares under the scheme, which currently has 187,681,267 restricted shares available for future grants. The Board, including independent non-executive directors, has deemed the grant as fair and reasonable, considering it beneficial for the interests of the company and its shareholders. The restricted shares are ordinary shares with a nominal value of US$1/120,000 each.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL4XqJSS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417516902.SGD","LU0516422952.EUR","LU1242518931.SGD","LU0327786744.USD","BK1589","LU0320764599.SGD","LU0823426480.USD","BK1576","LU1242518857.USD","LU0417516738.SGD","LU0588546209.SGD","LU1794554557.SGD","BK1610","LU1880383366.USD","BK1141","LU1688375341.USD","02269","SG9999002562.SGD","LU0348825331.USD","LU1720050803.USD","LU2039709279.SGD","LU0051755006.USD","LU0181495838.USD","LU0043850808.USD","LU0979878070.USD","LU0039217434.USD","LU0307460666.USD","LU0708995583.HKD","SG9999002463.SGD","LU0516422366.SGD","LU0516422440.USD","LU0823426308.USD","LU0516423091.SGD","LU0856984785.SGD","BK1521","LU0572944931.SGD","LU0359201612.USD","LU0819121731.USD","LU0052750758.USD","LU0456846285.SGD","LU0516423174.USD","LU0140636845.USD","IE00B0JY6N72.USD","LU0326950275.SGD","LU0456827905.SGD","LU0348735423.USD","LU0359202008.SGD"],"gpt_icon":1},{"id":"2540051652","title":"Genscript Biotech's Myeloma Drug Shows Progression-Free Survival in One-Third of Patients During Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2540051652","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540051652?lang=en_us&edition=fundamental","pubTime":"2025-06-04 17:46","pubTimestamp":1749030408,"startTime":"0","endTime":"0","summary":"Genscript Biotech (HKG:1548) subsidiary Legend Biotech said one-third of patients with relapsed/refractory multiple myeloma in its ciltacabtagene autoleucel study showed progression-free survival for ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1576","HK0000320264.USD","HK0000306701.USD","HK0000320223.HKD","BK1141","BK1583","01548","HK0000306685.HKD"],"gpt_icon":0},{"id":"2540640030","title":"VIVA Biotech Holdings Issues Clarification on Connected Transaction with Nanjing Entities","url":"https://stock-news.laohu8.com/highlight/detail?id=2540640030","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540640030?lang=en_us&edition=fundamental","pubTime":"2025-06-04 16:32","pubTimestamp":1749025941,"startTime":"0","endTime":"0","summary":"Viva Biotech Holdings has issued a supplemental announcement to clarify details regarding a connected transaction involving the establishment of a limited partnership fund. The company emphasized that several limited partners under the joint venture are ultimately controlled by the Nanjing Jiangbei New Area Management Committee, a governmental body. All other information in the original announcement remains unchanged.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VIVA Biotech Holdings published the original content used to generate this news brief on June 04, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL7gb812:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01873","BK1576","BK1141"],"gpt_icon":0},{"id":"2540250770","title":"Legend Biotech Announces Promising Phase 1 Results for LB2102 CAR-T Therapy in Lung Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2540250770","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540250770?lang=en_us&edition=fundamental","pubTime":"2025-06-03 22:45","pubTimestamp":1748961928,"startTime":"0","endTime":"0","summary":"Legend Biotech Corporation has announced promising interim results from a Phase 1 study of LB2102, a DLL3-targeted CAR-T cell therapy, in patients with lung cancers. The study, presented at a recent conference, involved patients with relapsed or refractory small-cell lung cancer  and large cell neuroendocrine carcinoma  who had received at least one prior line of therapy. The results indicated that LB2102 was well tolerated, with no dose-limiting toxicities observed up to Dose Level 4. The study also showed encouraging signs of dose-dependent efficacy, with clinical responses correlating with CAR-T cell expansion. These findings support continued dose escalation and further clinical evaluation. Legend Biotech is conducting this study in the U.S. under an exclusive global license agreement with Novartis Pharma AG.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDLFvntG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2095319765.USD","BK1583","BK1141","BK4588","IE00B64PRP62.GBP","LU2210149790.SGD","BK4505","IE00BGHQF748.EUR","HK0000320223.HKD","01548","HK0000306701.USD","BK4585","NDAQ","BK4112","IE00B3QW5Z07.USD","IE00BKPKM429.USD","HK0000320264.USD","LEGN","HK0000306685.HKD","BK1576","LU2210150020.SGD"],"gpt_icon":0},{"id":"2540797988","title":"Frontage Holdings Corporation Expands with New State-of-the-Art CRDMO Facility in Exton, PA","url":"https://stock-news.laohu8.com/highlight/detail?id=2540797988","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540797988?lang=en_us&edition=fundamental","pubTime":"2025-06-03 01:23","pubTimestamp":1748885034,"startTime":"0","endTime":"0","summary":"Frontage Laboratories, Inc., part of Frontage Holdings Corporation, has expanded its capabilities with the launch of a new Contract Research, Development, and Manufacturing Organization  facility in Exton, Pennsylvania. This state-of-the-art, 46,300-square-foot Good Manufacturing Practice  facility enhances Frontage's service offerings in drug substance synthesis, DMPK, safety & toxicology studies, bioanalysis, and clinical trial support. The facility features nine GMP suites tailored to diverse manufacturing needs, including high-potent, aseptic, and non-sterile suites, and is equipped to handle a variety of pharmaceutical forms such as injectables, tablets, and nasal preparations. The expansion underscores Frontage's commitment to accelerating pharmaceutical and biotech innovation by providing a comprehensive, one-stop-shop solution for clinical supplies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to pro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDL13qDBN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0174","300347","BK0028","BK0216","01521","BK1583","BK1576","BK1141","LU1146622755.USD","LU1820825898.SGD","BK0077"],"gpt_icon":0},{"id":"2539226891","title":"Wuxi Biologics Files Next Day Disclosure to HKEX: Announces Issuance of 3,653,100 New Shares at HKD 1.29-1.98","url":"https://stock-news.laohu8.com/highlight/detail?id=2539226891","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539226891?lang=en_us&edition=fundamental","pubTime":"2025-05-29 20:46","pubTimestamp":1748522779,"startTime":"0","endTime":"0","summary":"Wuxi Biologics  Inc. has filed a next day disclosure return with the Hong Kong Stock Exchange, reporting the issuance of a total of 3,653,100 new shares. These shares were issued as part of the exercise of share options under the company's Pre-IPO Share Option Scheme. The shares were issued at prices of HKD 1.98 and HKD 1.29.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics  Inc. published the original content used to generate this news brief on May 29, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDL2GGShQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0039217434.USD","LU1242518857.USD","LU0456827905.SGD","LU0181495838.USD","02269","LU1720050803.USD","LU0516422366.SGD","LU0823426308.USD","IE00B0JY6N72.USD","SG9999002463.SGD","LU1242518931.SGD","BK1141","LU2039709279.SGD","LU0052750758.USD","LU0307460666.USD","LU0326950275.SGD","LU0327786744.USD","LU0516422440.USD","LU0043850808.USD","LU0359201612.USD","LU0979878070.USD","LU0051755006.USD","LU0516423091.SGD","SG9999002562.SGD","LU0320764599.SGD","BK1521","LU1794554557.SGD","LU0348825331.USD","LU0516422952.EUR","LU0708995583.HKD","LU0417516738.SGD","BK1610","LU0417516902.SGD","LU0572944931.SGD","BK1589","BK1576","LU0456846285.SGD","LU1688375341.USD","LU0819121731.USD","LU0588546209.SGD","LU0823426480.USD","LU0348735423.USD","LU1880383366.USD","LU0856984785.SGD","LU0516423174.USD","LU0359202008.SGD","LU0140636845.USD"],"gpt_icon":1},{"id":"2538479517","title":"Frontage Holdings Corporation Conducted Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2538479517","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538479517?lang=en_us&edition=fundamental","pubTime":"2025-05-28 21:04","pubTimestamp":1748437445,"startTime":"0","endTime":"0","summary":"Frontage Holdings Corporation held its Annual General Meeting on May 28, 2025. All resolutions proposed at the meeting were approved. Dr. Zhihe Li ceased to be a Non-executive Director, while Dr. Wentao Zhang and Dr. Zhongping Lin were appointed as Executive Directors. The Board expressed gratitude to Dr. Zhihe Li for contributions during the tenure and welcomed the new members.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Frontage Holdings Corporation published the original content used to generate this news brief on May 28, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL8Vq3cM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01521","LU1820825898.SGD","BK0174","BK0216","LU1146622755.USD","BK0028","BK1576","BK1141","BK1583","300347","BK0077"],"gpt_icon":0},{"id":"2538422682","title":"BRIEF-Viva Biotech Says Hangzhou Viva Zongchen Agreed To Invest RMB25.0 Million To Fund","url":"https://stock-news.laohu8.com/highlight/detail?id=2538422682","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538422682?lang=en_us&edition=fundamental","pubTime":"2025-05-28 18:10","pubTimestamp":1748427057,"startTime":"0","endTime":"0","summary":"BRIEF-Viva Biotech Says Hangzhou Viva Zongchen Agreed To Invest RMB25.0 Million To FundMay 28  - VIVA Biotech Holdings 1873.HK:HANGZHOU VIVA ZONGCHEN AGREED TO INVEST RMB25.0 MILLION TO FUNDFUND REFERS TO LIMITED PARTNERSHIP FUND TO BE NAMED NANJING HONGHUI WEITAI VENTURE CAPITAL FUND PARTNERSHIPFurther company coverage: 1873.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nFWN3S00MU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","BK1576","01873"],"gpt_icon":0},{"id":"2538249423","title":"VIVA Biotech - Fund Refers to Limited Partnership Fund to Be Named Nanjing Honghui Weitai Venture Capital Fund Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2538249423","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538249423?lang=en_us&edition=fundamental","pubTime":"2025-05-28 16:51","pubTimestamp":1748422302,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nFWN3S00MU:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01873","BK1576","BK1141"],"gpt_icon":0},{"id":"2538232454","title":"VIVA Biotech - Hangzhou Viva Zongchen Agreed to Invest RMB25.0 Mln to Fund","url":"https://stock-news.laohu8.com/highlight/detail?id=2538232454","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538232454?lang=en_us&edition=fundamental","pubTime":"2025-05-28 16:51","pubTimestamp":1748422302,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nFWN3S00MU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1576","01873","BK1141"],"gpt_icon":0},{"id":"2538793501","title":"WuXi AppTec Cuts Conversion Price of Zero-Coupon Bonds Due This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2538793501","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538793501?lang=en_us&edition=fundamental","pubTime":"2025-05-26 17:04","pubTimestamp":1748250265,"startTime":"0","endTime":"0","summary":"WuXi AppTec  will lower the conversion price of its $500 million zero-coupon convertible bonds due 2025, according to a Friday filing with the Hong Kong Exchange.As a result of shareholders' approval of the 2024 profit distribution and 2025 special dividend, the conversion price will drop from HK$80.02 to HK$78.28 per H Share, effective May 24.This adjustment increases the potential convertible shares from about 48.5 million to 49.6 million, representing roughly 12.81% of current issued shares and 11.36% after full conversion.Shares of the pharma company were down about 3% at market close on Monday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1576","LU0708995583.HKD","LU2125910500.SGD","LU1046422090.SGD","BK1141","02359","LU2242644610.SGD","BK1583","LU0052750758.USD","LU2045819591.USD","LU0320764599.SGD"],"gpt_icon":0},{"id":"2537907216","title":"Joinn Laboratories Affiliate Buys Deposit Products for 440 Million Yuan; Hong Kong Shares Up 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2537907216","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537907216?lang=en_us&edition=fundamental","pubTime":"2025-05-23 15:33","pubTimestamp":1747985580,"startTime":"0","endTime":"0","summary":"Joinn Laboratories   said an affiliate subscribed for Bank of Jiangsu's  four deposit products for 440 million yuan, according to a Hong Kong bourse filing on Thursday.The four products include a 150 million yuan floating-income product with an expected return of 0.1% to 2.45% maturing on May 22, a 60 million yuan plan offering 1.6%to 2.50% maturing on Dec. 27, a 200 million yuan investment yielding 1% to 2.56% maturing on Aug. 26, and a 30 million yuan structured deposit with a return of either 1.50% or 2.45% percent maturing on Nov. 23.Joinn Laboratories, a Chinese provider of preclinical and non-clinical research services, expects total interest from the investments to range from 74,000 yuan to 2.5 million yuan.The company's Hong Kong shares jumped less than 7% in recent trade. Shanghai shares closed less than 3% higher.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1141","603127","BK0216","BK1576","06127"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":17,"code":"91000000","status":"200"}]}}